Pyruvate metabolism and extracellular matrix remodelling in the targeting of metastatic cancer
Metastases, or secondary tumours, are the leading cause of cancer deaths. Many breast cancer patients get the diagnosis when cancer cells have already disseminated to distant organs. Extracellular matrix (ECM) remodelling in the metastatic niche is essential for disseminated breast cancer cells to promote the growth of the new metastasis. The host laboratory has recently discovered that the nutrient pyruvate metabolically drives breast cancer cells to remodel the ECM. The EU-funded MetaTarGet project is capitalising on this discovery to explore the potential targeting of ECM remodelling in metastasis. The research will focus on pyruvate metabolism as an ECM remodelling regulator and a novel therapeutic strategy to target metastatic outgrowth.